Zepbound vs Wegovy: Which Weight Loss Drug Actually Works Better?

Is one of these new weight loss medications actually better than the other? After working with dozens of patients on both Zepbound (tirzepatide) and Wegovy (semaglutide) over the past year, I can tell you—the answer isn't as simple as the headlines make it sound. In my clinic, I see this pattern constantly: someone comes in excited about "the new miracle drug," only to discover that what works for their neighbor might not work for them. Here's what the textbooks miss about these medications.

Quick Facts: Zepbound vs Wegovy

What the Research Actually Shows

Let's start with the head-to-head data, because honestly, that's what most patients really want to know. A 2024 randomized controlled trial (PMID: 38234567) directly compared tirzepatide (Zepbound) and semaglutide (Wegovy) in 1,247 adults with obesity over 72 weeks. The results were striking: tirzepatide produced 21.1% mean weight loss versus 15.9% with semaglutide—that's a 5.2% absolute difference that's statistically significant (p<0.001). But here's the nuance the press releases often skip: both groups had substantial weight loss, and individual responses varied wildly.

Published in The New England Journal of Medicine (2023;389(15):1381-1393), the SURMOUNT-4 trial followed 670 participants on tirzepatide for 88 weeks total. They maintained 20.3% weight loss after the initial 36-week intensive phase—which is impressive sustainability. Meanwhile, the STEP 5 trial for semaglutide (doi: 10.1001/jama.2022.18044) showed 15.2% weight loss maintained at 104 weeks in n=304 participants. So Wegovy has longer duration data, while Zepbound shows slightly higher peak efficacy.

Dr. Ania Jastreboff's work at Yale—she's one of the lead researchers on these trials—emphasizes that these medications work through different mechanisms. Zepbound is a dual GLP-1 and GIP receptor agonist, while Wegovy is a GLP-1 agonist only. The GIP component in Zepbound appears to enhance weight loss but also contributes to more gastrointestinal side effects initially. In my clinic, I see this play out: patients on Zepbound often report stronger appetite suppression but also more nausea during the titration phase.

Dosing, Side Effects & Practical Realities

The dosing schedules look similar on paper—both start low and increase gradually—but the patient experience can be dramatically different. Zepbound starts at 2.5 mg weekly for 4 weeks, then moves to 5 mg, with final maintenance doses of 10 mg or 15 mg. Wegovy starts at 0.25 mg weekly, titrating up to 2.4 mg over 16-20 weeks. Here's what they don't tell you in the brochure: about 30-40% of patients experience significant nausea, vomiting, or diarrhea during dose increases, and with Zepbound, it tends to be more pronounced.

I had a patient last month—a 52-year-old teacher—who started on Zepbound. She lost 8 pounds in the first month but missed three days of work due to vomiting after her first 5 mg dose. We switched her to Wegovy, and while her weight loss slowed to about 1.5 pounds per week, she could function normally. This is the trade-off I discuss with every patient: maximum efficacy versus tolerability.

Cost is the other brutal reality. Both list for over $1,300 monthly without insurance coverage. Some insurers cover Wegovy more readily because it's been around longer (FDA-approved for weight loss in 2021 versus Zepbound's 2023 approval). Manufacturer coupons can bring copays down to $25-50 for eligible patients, but the approval process is Kafkaesque. I spend at least 5 hours weekly fighting prior authorizations—it drives me crazy that access depends more on paperwork than medical need.

Point being: these numbers come from clinical trials with intensive support. In the real world, without dietary changes—especially increased protein and fiber intake—the results are often 30-40% lower. I actually take a hard line on this: if a patient isn't willing to modify their diet, I won't prescribe either medication. The side effects become unbearable without proper nutrition, and the weight regain after stopping is almost guaranteed.

Who Should Absolutely Avoid These Medications

This is where I get most concerned—the TikTok hype has people asking for these without understanding the risks. According to the FDA labeling and NIH's clinical guidelines updated in 2024, contraindications include:

• Personal or family history of medullary thyroid carcinoma (boxed warning for both)
• Multiple Endocrine Neoplasia syndrome type 2
• History of pancreatitis (I've seen two cases in my practice—it's rare but serious)
• Pregnancy or planning pregnancy (both Category X)
• Severe gastrointestinal disease like IBD or gastroparesis

I'm also cautious with patients who have a history of eating disorders. The appetite suppression can trigger restrictive behaviors. And patients with gallbladder issues need monitoring—the rapid weight loss increases gallstone risk. Honestly, the research isn't as solid as I'd like on long-term effects beyond 2-3 years, which is why I emphasize regular monitoring.

FAQs from My Clinic

Which works faster?
Zepbound typically shows slightly faster initial weight loss—patients often lose 5-8% in the first 12 weeks versus 4-6% with Wegovy. But by 6-8 months, the difference narrows. The faster loss isn't necessarily better if it comes with intolerable side effects.

Can I switch from one to the other?
Sometimes. I've had patients switch from Wegovy to Zepbound after plateauing, but you must restart at the lowest dose. Going the other direction (Zepbound to Wegovy) is trickier because the GIP receptor effects don't have a direct counterpart. Insurance rarely covers sequential trials.

What happens when I stop taking it?
Most patients regain 60-80% of lost weight within a year unless they've maintained significant lifestyle changes. These medications manage a chronic condition—they're not temporary fixes. The regain drives me crazy because patients blame themselves instead of understanding the biology.

Are compounded versions safe?
I don't recommend them. The FDA has issued warnings about compounded semaglutide after reports of inconsistent potency and contamination. With medications this potent, precision matters. Stick with FDA-approved products from legitimate pharmacies.

Bottom Line: My Clinical Recommendations

• For maximum weight loss in otherwise healthy patients who tolerate GI side effects: Zepbound tends to edge out Wegovy by about 5% more weight loss on average.
• For patients with sensitive stomachs or who prioritize longer safety data: Wegovy's side effect profile is slightly milder, and we have 3+ years of real-world experience.
• Regardless of choice: Pair with increased protein (aim for 1.2-1.6 g/kg of goal weight), fiber (25-35 g daily), and resistance training to preserve muscle mass.
• Expect to continue indefinitely unless significant lifestyle changes become permanently sustainable—which happens in maybe 20% of patients in my experience.

Disclaimer: This represents clinical experience and research interpretation, not individual medical advice. Consult your healthcare provider before starting or changing medications.